Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of EGFR-mutant NSCLC, substantially improving clinical outcomes (Shirley and Keam, 2022; Wang et al., 2022). This evidence concerns the gene EGFR and non-small cell lung carcinoma.